Julia Appelskog was Head of PV Strategy Office, Global Patient Safety, at Merck KGaA. She has more than 17 years of experience in Pharmacovigilance and 8 years of experience in biomedical research. Previous roles include EU QPPV and Head of Pharmacovigilance at Bluefish Pharmaceuticals, and senior PV positions within large pharma companies, such as MSD, Johnson & Johnson and Sanofi Pasteur MSD. Her expertise spans the entire product life cycle covering medicinal products, including biopharmaceuticals and vaccines, medical device and cosmetics.
Dr. Appelskog has accomplished a Ph.D. Thesis in cell biology at the Karolinska Institute (Sweden) in 2001, focusing on diabetes research for 8 years. She has been a postdoctoral fellow at the Department of Clinical Neuroscience at Karolinska Institute, conducting research on epigenetic mechanisms, modification of DNA and its associated proteins in tumor cells.